8-K: Synlogic Announces Executive Leadership Transition: Antoine Awad to Depart, Mary Beth Dooley Appointed CEO and CFO

Synlogic, Inc. has announced the departure of its Principal Executive Officer, Antoine Awad, effective December 31, 2024, and the appointment of Mary Beth Dooley as the new Principal Executive Officer and Principal Financial Officer, effective January 1, 2025.

Summary

• Synlogic, Inc. has entered into a separation agreement with its Principal Executive Officer, Antoine Awad, who will depart on December 31, 2024.
• Mr. Awad will receive a lump-sum payment of $218,856, equivalent to six months of his base salary, and is eligible for 100% of his 2024 target bonus.
• He will also receive $246,213, representing 75% of his base salary for each month of service between March 1, 2024, and December 31, 2024.
• Mr. Awad will receive continued health insurance coverage for up to six months following his departure.
• Synlogic has also entered into a consulting agreement with Mr. Awad, paying him $350 per hour for project-based services.
• The consulting agreement extends the exercise period of his stock options and accelerates vesting upon a change of control or dissolution.
• Mary Beth Dooley, the current Head of Finance, has been appointed as the new Principal Executive Officer and Principal Financial Officer, effective January 1, 2025.
• Ms. Dooley will receive an annual base salary of $325,000 and a target annual bonus of $97,500 for 2024.
• She is also eligible for a retention bonus equal to 75% of her base salary for each month of service between March 1, 2024, and a change in control or termination without cause.
• Ms. Dooley's stock options and restricted stock grants have been amended to extend the exercise period and accelerate vesting upon a change of control, dissolution, or termination without cause.

Sentiment

Score: 6

Explanation: The document outlines a planned executive transition, which is a neutral event. While there are some costs associated with the separation, the company has a clear succession plan in place. The sentiment is therefore slightly positive.

Positives

• The company has a clear succession plan in place with the appointment of Mary Beth Dooley as the new CEO and CFO.
• The consulting agreement with Mr. Awad ensures a smooth transition and continued access to his expertise.
• Ms. Dooley's retention bonus provides an incentive for her to remain with the company through a potential change in control.
• The acceleration of vesting for both Mr. Awad and Ms. Dooley's equity grants upon a change in control aligns their interests with shareholders.

Negatives

• The departure of the Principal Executive Officer may create uncertainty for the company.
• The company will incur significant costs related to Mr. Awad's separation package and consulting fees.
• Ms. Dooley will not be eligible for any bonus in respect of 2025 or any subsequent year.

Risks

• The transition in leadership could potentially disrupt ongoing projects and strategic initiatives.
• The company's performance could be affected by the change in executive leadership.
• The consulting agreement with Mr. Awad could create potential conflicts of interest.

Future Outlook

The company is focused on ensuring a smooth transition of leadership and continuing its operations under the new leadership of Mary Beth Dooley. The company will file the full text of the agreements as exhibits to the annual report on Form 10-K for the year ending December 31, 2024.

Management Comments

• The company and Antoine Awad agreed that Mr. Awad's employment would terminate effective December 31, 2024.
• Mr. Awad will assist the company through the Awad Departure Date in the transition of work.
• The company's board of directors appointed Mary Beth Dooley as the Principal Executive Officer and Principal Financial Officer, effective January 1, 2025.

Industry Context

Executive transitions are common in the biotechnology industry, especially in companies undergoing strategic shifts or facing financial challenges. The appointment of a new CEO and CFO often signals a change in direction or a renewed focus on operational efficiency and financial stability. The use of consulting agreements to ensure a smooth transition is also a common practice.

Comparison to Industry Standards

• The separation package for Mr. Awad, including a lump-sum payment and continued health insurance, is generally in line with industry standards for executive departures.
• The consulting agreement with Mr. Awad is a common practice to ensure a smooth transition and knowledge transfer, similar to what is seen in other biotech companies.
• The compensation package for Ms. Dooley, including a base salary, bonus, and retention bonus, is competitive with other executive roles in the biotechnology sector.
• The acceleration of vesting for equity grants upon a change in control is a standard practice to align executive interests with shareholders, similar to what is seen in other companies such as Amgen and Biogen.

Management Changes

Stakeholder Impact

• Shareholders may react to the leadership change, potentially impacting the stock price.
• Employees will experience a change in leadership, which may affect morale and company culture.
• Customers and suppliers may not be directly impacted by this change.

Next Steps

• The company will file the full text of the Awad Separation Agreement and the Amended Employment Agreement with Ms. Dooley as exhibits to the annual report on Form 10-K for the year ending December 31, 2024.
• Mr. Awad will provide consulting services to the company as needed.
• Ms. Dooley will assume her new roles as Principal Executive Officer and Principal Financial Officer on January 1, 2025.

Key Dates

Keywords

executive transition, CEO, CFO, separation agreement, consulting agreement, leadership change, compensation, stock options, retention bonus, Synlogic